Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia.

Journal Article (Review)

Anemia is common in patients treated with chemotherapy for both solid and hematologic malignancies, contributing to fatigue and diminished quality of life and exposing them to the inherent risks of red blood cell transfusions. Erythropoiesis-stimulating proteins have been shown to increase hemoglobin levels, reduce the need for transfusions, and improve quality of life. The current practice guidelines recommend treating moderate to severe chemotherapy-induced anemia with erythropoiesis-stimulating proteins, but the risk of transfusions may be less with earlier intervention at higher hemoglobin levels. A review of the literature suggests that treating mild chemotherapy-induced anemia with erythropoiesis-stimulating proteins reduces the risks of transfusions and the development of more-severe anemia. Weighing the clinical evidence together with other clinical and economic considerations should provide greater insight into the benefits of treating mild anemia in patients treated with chemotherapy.

Full Text

Duke Authors

Cited Authors

  • Lyman, GH

Published Date

  • July 2006

Published In

Volume / Issue

  • 20 / 8 Suppl 6

Start / End Page

  • 16 - 20

PubMed ID

  • 16925106

International Standard Serial Number (ISSN)

  • 0890-9091

Language

  • eng

Conference Location

  • United States